Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | CNR1 | P21554 | 10/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650810 | 0.80 | KMT2A (0.41) | CNR1KMT2A | |
| SCHEMBL5653100 | 0.78 | MAPT (0.40) | HTTCNR2CNR1PKMKMT2A | |
| SCHEMBL3687298 | 0.72 | CNR1 (0.48) | HTTCNR2CNR1 | |
| SCHEMBL3681869 | 0.72 | CNR1 (0.48) | HTTCNR2CNR1 | |
| SCHEMBL55036 | 0.68 | HTT (0.66) | HTTPKMMAPK8MAPK10ALDH1A1 | |
| SCHEMBL4367890 | 0.68 | HTT (0.60) | HTTCNR2CNR1PKMMAPK8 | |
| SCHEMBL12629113 | 0.67 | CYP2D6 (0.71) | HTTCNR1ALDH1A1KMT2A | |
| SCHEMBL2999120 | 0.67 | HTT (0.69) | HTTPKMALDH1A1KMT2A | |
| SCHEMBL5651444 | 0.67 | PRMT5 (0.59) | HTT | |
| SCHEMBL5406540 | 0.67 | HTT (0.73) | HTTPKMALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | HTT 4354/4885CNR2 129/4885CNR1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.